683 Capital Management »

Atrium Therapeutics shares owned by 683 Capital Management

Quarter-by-quarter ownership of Atrium Therapeutics (RNA) shares owned by 683 Capital Management from 13F filings

Historical chart of 683 Capital Management investment in Atrium Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Atrium Therapeutics held by 683 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Atrium Therapeutics by 683 Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $4.0M 300k 13.37

More positions owned by 683 Capital Management

Palantir Technologies Cl A Put Option (PLTR)
Eli Lilly & Co. (LLY)
NVIDIA Corporation Put Option (NVDA)
Capital One Financial (COF)
Alnylam Pharmaceuticals (ALNY)
Carvana Cl A (CVNA)
Madrigal Pharmaceuticals Put Option (MDGL)
Tesla Motors Put Option (TSLA)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Protagonist Therapeutics (PTGX)
Praxis Precision Medicines I Com New Put Option (PRAX)
Wave Life Sciences SHS (WVE)
Becton, Dickinson and (BDX)
Kaspi Kz Jsc Sponsored Ads (KSPI)
Anaptysbio Inc Common (ANAB)

View all positions for 683 Capital Management

Top funds holding Atrium Therapeutics

BlackRock
RA Capital Management
Vanguard Capital Management
TIG Advisors
Pentwater Capital Management
Sessa Capital IM
Goldman Sachs Group
Vanguard Portfolio Management
Geode Capital Management
683 Capital Management
Weiss Asset Management LP[1
Cantor Fitzgerald, L. P.
Balyasny Asset Management
Squarepoint Ops
Fort Hoosac Management

View all funds holding Atrium Therapeutics